Decreased estrogen receptor and progesterone receptor expression associated with neoadjuvant therapy of exemestane in combination with celecoxib in postmenopausal women with breast cancer

被引：0
|
作者：
deHart, J. R. [1 ]
Jimenez, R. E. [1 ]
Shapiro, C. L. [1 ]
Povoski, S. P. [1 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Richard J Solove Res Inst, Columbus, OH 43210 USA
来源：
MODERN PATHOLOGY | 2007年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
108
引用
收藏
页码：28A / 28A
页数：1
相关论文
共 50 条
  • [1] Decreased estrogen receptor and progesterone receptor expression associated with neoadjuvant therapy of exemestane in combination with celecoxib in postmenopausal women with breast cancer
    deHart, J. R.
    Jimenez, R. E.
    Shapiro, C. L.
    Povoski, S. P.
    LABORATORY INVESTIGATION, 2007, 87 : 28A - 28A
  • [2] Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
    Lustberg, Maryam B.
    Povoski, Stephen P.
    Zhao, Weiqiang
    Ziegler, Rebecca M.
    Sugimoto, Yasuro
    Ruppert, Amy S.
    Lehman, Amy M.
    Shiels, Donna R.
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Layman, Rachel M.
    Brueggemeier, Robert W.
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2011, 11 (04) : 221 - 227
  • [3] Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor-or Progesterone Receptor-Positive Breast Cancer
    Forero-Torres, Andres
    Saleh, Mansoor N.
    Galleshaw, Janice A.
    Jones, Cheryl F.
    Shah, Jatin J.
    Percent, Ivor J.
    Nabell, Lisle M.
    Carpenter, John T.
    Falkson, Carla I.
    Krontiras, Helen
    Urist, Marshall M.
    Bland, Kirby I.
    De Los Santos, Jennifer F.
    Meredith, Ruby F.
    Caterinicchia, Valerie
    Bernreuter, Wanda K.
    O'Malley, Janis P.
    Li, Yufeng
    LoBuglio, Albert F.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 275 - 280
  • [4] The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer
    Lee, SH
    Chung, MA
    Quddus, MR
    Steinhoff, MM
    Cady, B
    AMERICAN JOURNAL OF SURGERY, 2003, 186 (04): : 348 - 350
  • [5] Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women
    R L Balleine
    M J Earl
    M L Greenberg
    C L Clarke
    British Journal of Cancer, 1999, 79 : 1564 - 1571
  • [6] Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women
    Balleine, RL
    Earl, MJ
    Greenberg, ML
    Clarke, CL
    BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) : 1564 - 1571
  • [7] Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
    O'Shaughnessy, J.
    Campone, M.
    Brain, E.
    Neven, P.
    Hayes, D.
    Bondarenko, I.
    Griffin, T. W.
    Martin, J.
    De Porre, P.
    Kheoh, T.
    Yu, M. K.
    Peng, W.
    Johnston, S.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 106 - 113
  • [8] Alternation of Estrogen Receptor and Progesterone Receptor Expression in Primary Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Kitagawa, Dai
    Saji, Shigehira
    Horiguchi, Shin-ichiro
    Satoh, Yu
    Horiguchi, Kazumi
    Toi, Masakazu
    Funata, Nobuaki
    Kuroi, Katsumasa
    BREAST JOURNAL, 2010, 16 (04): : 435 - 436
  • [9] Changes of estrogen receptor, progesterone receptor and HER2 expression in breast cancer with/without neoadjuvant chemotherapy or endocrine therapy
    Maeda, Shigeto
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma
    Moreno, Gustavo A.
    Molina, Mariel, I
    Eastwood, Dan
    Auer, Paul L.
    Jorns, Julie M.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (03) : 453 - 461
12345